webinar recording available - register to watch

The power of antigen-specific TCR signatures in developing next-gen immunotherapies

Discover the diverse applications of T-cell receptor (TCR) sequencing to identify antigen-specific T-cell responses and accelerate the development of next-generation cancer immunotherapies. This webinar highlights TCR signatures linked to cancer biomarkers and their potential applications in clinical trials. These findings provide clinically actionable insights into the adaptive immune response to immunotherapy. Adaptive’s presentation includes T cell response data in patients with advanced urothelial carcinoma, where TCR signatures were tracked before and after treatment with atezolizumab. Meaningful TCR repertoire changes were associated with clinical efficacy and favorable patient outcomes, specifically for mutations such as FGFR3, CTNNB1, ERBB2, and EGFR.

These findings are supported by Adaptive Biotechnologies’ unparalleled immunomics database, containing more than 1 million TCRs mapped to nearly 800 clinically relevant neoantigens, tumor-associated antigens and oncoviruses. This database provides a unique approach to better understand TCR-antigen interactions across different solid tumor types and to comprehensively draw robust conclusions regarding the efficacy of a given drug.

The webinar will also introduce the Visualizer platform, a web-based application that allows researchers to explore immunosequencing data interactively. The platform supports dynamic visualization, integration of trial- and patient-specific metadata, and iterative data analyses, facilitated by Adaptive's Translational Sciences team.

What You'll Learn:

Application of cancer antigen-specific TCR signatures in clinical trials.
The role of TCR deep sequencing as a valuable biomarker of response.
Launch of the Visualizer platform to support comprehensive, user-friendly data analyses.

watch now

watch the webinar

First name

Last name

Company

Job Title

Country

Does your group focus solely on Oncology?

Do you work in early trials (preclinical and/or phase 1/2) or late-stage (phase 2 and phase 3) clinical trials?

Have you previously worked with Adaptive?

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Stephanie Bien

Associate Director, Translational Science, Adaptive Biotechnologies

Stephanie Bien, PhD, has more than 12 years of research experience in genetic epidemiology and is an expert in the field of immunosequencing. Her current role as Associate Director at Adaptive is focused on partnering with clinical researchers and therapeutic developers to incorporate Adaptive’s immunosequencing technology into their translational research pipelines. Stephanie earned a PhD in Public Health Genetics at the University of Washington where she specialized in biomarker development through integrative multi-omics data.

Harsh Patel

Translational Scientist, Adaptive Biotechnologies

Harsh Patel, PhD, has more than 6 years of research experience in genomics and healthcare informatics and has deep understanding in the field of developing usable research software. Currently at Adaptive, Harsh is a Translational Scientist who aids partners utilize Adaptive’s immunosequencing technology to further their understanding of how the immune system interacts with different exposures or therapies. Harsh earned a PhD from the University of Washington in Biomedical and Health Informatics where he specialized in enabling novice multi-omics researchers by developing user-centered analysis tools.

moderator

Surani Fernando

Healthcare journalist, writer & podcaster

Surani Fernando is a seasoned healthcare journalist and editor with over 13 years experience covering the biopharma industry. A Sydney native, she started her investigative journalism career in London covering clinical trials, M&A and financing deals for BioPharm Insight, later moving to New York to continue her work as an enterprise journalist and editorial leader for GlobalData and Reorg. She is now based in Madrid working as a freelance journalist, consultant writer and podcast producer. In November 2023, she launched the Raising Biotech podcast.